EC conditionally approves MSD’s Welireg for VHL disease and RCC
The EC has conditionally approved MSD's Welireg as a single agent for the treatment of adults with VHL disease and advanced clear cell RCC.
The EC has conditionally approved MSD's Welireg as a single agent for the treatment of adults with VHL disease and advanced clear cell RCC.
What's Your Reaction?
